d-Wise Announces “Blur” De-identification Solution at DIA Annual 2015

Share Article

Life Science technology leader d-Wise unveils Blur, the industry-leading solution for delivering de-identified clinical trial data and protecting patient privacy.

June 15, 2015 (PRWEB) June 15, 2015 -- d-Wise Technologies, a leading life science and healthcare technology solutions provider, announced the availability of their latest software solution, Blur, at the DIA Annual 2015 conference. The Blur de-identification solution is specifically designed to address patient privacy and support clinical data transparency and sharing initiatives. Blur delivers high performance, application-driven, data de-identification to safeguard patient privacy while reducing the overall costs associated with the de-identification process. The solution has integrated workflow and controls, learned intelligence, and accommodates established as well as emerging de-identification rules.

AstraZeneca, a top pharmaceutical company, has licensed the solution and is in the process of deploying it for external data de-identification, in support of their transparency initiatives, as well as, deploying it for internal data de-identification. “d-Wise is excited to have partnered with AstraZeneca on the development of this industry leading solution”, stated John Leveille, CEO at d-Wise. “Their expertise has been extremely helpful in the development and refinement of our solution, and we strongly believe that other biopharmaceutical companies will see value in the solution for their own organizations.”

Biopharmaceutical companies have been anonymizing data on a small scale for years, but the era of clinical trial data transparency and sharing initiatives has changed the rules. The need to share clinical trial data with external collaborators (like independent researchers) and internal partners (like planning, modeling and exploration teams) has never been greater. As data sharing needs accelerate in terms of volume and urgency, the old ways of delivering anonymized data are no longer practical. Blur was developed by pharmaceutical industry experts and represents the most modern approach to patient-level data de-identification available today. It requires far less internal development, maintenance and support than alternative scripting tools , and brings scalability to the clinical trials de-identification process.

Blur is easily deployed through a simple browser interface, and incorporates a wide variety of clinical trials and healthcare de-identification rules that can be customized to individual projects. The availability of a point-and-click interface, instead of a programming interface, means that Blur can be used by a broad set of users providing considerably more flexibility than the current approaches being used today.

With more than 20 life sciences companies actively engaging in clinical trial data transparency and sharing initiatives, there is a clear need to streamline the availability of de-identified data.

To learn more about d-Wise’s solution, please visit http://www.d-wise.com/blur

About d-Wise
d-Wise Technologies, Inc. http://www.d-wise.com is a technology leader with the expertise to empower world-class life science and healthcare organizations to resolve their business optimization challenges, helping them rapidly harness and leverage data, systems and processes to gain competitive advantage.

The d-Wise Life Sciences Practice has been providing clinical advisory and modernization services to our clients for over a decade. d-Wise consultants work with Life Science clients to adopt a progressive and comprehensive approach to modernizing clinical trial solutions and processes. d-Wise helps identify existing business problems – systems, processes, architecture, etc. – that inhibit your ability to achieve your clinical research goals. We then enable you to reach those goals by modernizing your software and solutions, business processes, and infrastructure. We tailor all solutions to meet individual client needs and deliver data integration, data warehousing and standards solutions within highly-regulated industries with expertise is rooted in extensive domain knowledge of SAS software, clinical drug development and clinical data standards like CDISC. Our end-to-end expertise and assessment services encompass business process and change management; data and metadata-driven strategies; and vendor-agnostic infrastructure and technology assessments
.
Within healthcare, d-Wise helps organizations develop an analytic vision, and integrate and streamline data operations for rapid deployment of visual intelligence solutions and advanced analytic models. d-Wise is well known for their expertise and capability to implement advanced analytic solutions that improve operations, lower costs, improve health outcomes quality and facilitate executive decision-making. We have a broad range of experience that includes data optimization for actuarial, quality, medical-management, and operational functions, as well as support for IT and data organizations looking to implement best practices.
###

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Keith W. Ward, Director, Global Marketing
kward@d-Wise.com
+1 (919) 334-6095
Email >